This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription pharmaceutical product. The contract has a value of $115,590.40 and a completion date of September 25, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide the specified medication to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract, valued at $46,236.16, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The order has an ultimate completion date of August 14, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded several federal contracts and indefinite delivery contracts (IDCs) by various defense and...
This federal contract award to AmerisourceBergen Drug Corp Corporate Office Division is a delivery order valued at $57,795.20 for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract is a firm fixed-price agreement with the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of September 3, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award, which is not set aside for any specific business type....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58, a firm fixed price pricing type, and a period of performance through February 4, 2025. This is a delivery order contract, not associated with a larger contracting vehicle. The...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract is a firm fixed price, non-set-aside award with a completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $115,590.40 fixed-price contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty medication. The contract has a ceiling value of $115,590.40 and an ultimate completion date of September 3, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of March 31, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $120,192.80 firm fixed-price contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The $34,677.12 firm fixed price contract is for the supply of OCREVUS 300 mg/10 ml vials, which are used for the treatment of multiple sclerosis. The contract has an ultimate completion date of September 27, 2024 and does not have a set-aside designation. As a major pharmaceutical distributor, AmerisourceBergen holds...
This is a $48,077.16 firm-fixed-price delivery order contract awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of July 2, 2025 and is not set aside for any particular business category. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...